Fifth, this study utilized molecular docking technology to verify the binding capacity of the active ingredients of XFC with the NF-κB pathway protein p65, providing direct molecular-level evidence for the mechanism of XFC in treating RA. Here, NFKB1 is linked to rheumatoid arthritis.